25537-64-8Relevant articles and documents
LPA RECEPTOR ANTAGONISTS AND USES THEREOF
-
, (2021/12/17)
The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non alcoholic steatohepatitis (NASH).
TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF
-
Paragraph 0286-0287, (2021/05/21)
The present disclosure relates generally to compounds of Formula (I) that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).
NEW TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM
-
Page/Page column 58-59, (2021/11/20)
The invention provides novel compounds having the general formula (I) or (II) wherein R1, R2, R3, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.
